Tumour immune barrier structure formation of SPP1+ macrophages and cancer‐associated fibroblasts (CAFs) limits the efficacy of immune therapy in HCC and dominant TLS in paratumour tissue instead of in tumour tissue featuring with immature phenotype represented immune excluded states with worst prognosis of ICC patients.14, 15. The gene discussed is SPP1; the disease is neoplasm.